NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
21
Data completeness
6/8 — Strong
Priority Review
ZEPBOUND (AUTOINJECTOR) (tirzepatide) by Eli Lilly and Company is g-protein-linked receptor interactions [moa]. Approved for glucose-dependent insulinotropic polypeptide receptor agonist [epc]. First approved in 2023.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEPBOUND (tirzepatide) is a subcutaneous, once-weekly GLP-1 and GIP receptor agonist approved by FDA on November 8, 2023, for chronic weight management in adults with obesity or overweight with weight-related comorbidities. It works via dual G-protein-coupled receptor signaling to enhance glucose-dependent insulin secretion and reduce appetite. The autoinjector formulation delivers tirzepatide solution subcutaneously for patient convenience.
Growth12.8 years to LOE
ZEPBOUND is in growth phase with modest current market presence but significant expansion potential as obesity treatment adoption accelerates; career positions will expand across commercial, access, and medical teams.
Mechanism of Action
G-Protein-linked Receptor Interactions
Pharmacologic Class:
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Started Jan 2027
70 enrolled
Obesity
Tirzepatide for Treatment of CCCA
Started Sep 2026
20 enrolled
Central Centrifugal Cicatricial Alopecia (CCCA)
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Started Sep 2026
18 enrolled
Diabetes Mellitus, Type 1OverweightObesity
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
Started Sep 2026
20 enrolled
Pouch, IlealPouches, IleoanalBowel Diseases, Inflammatory
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Started Sep 2026
150 enrolled
Obesity
Worked on ZEPBOUND (AUTOINJECTOR) at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.